7 June 2023

BerGenBio ASA: Mandatory notification of trade by Primary Insiders and close associates

Bergen 7 June 2023: Reference is made to the stock exchange announcement published by BerGenBio ASA (the “Company”) on 30 May 2023, regarding the commencement of the subscription period in the rights issue (the “Rights Issue”) and the receipt of subscription rights in the Rights Issue by certain primary insiders and certain close associates of primary insiders of the Company.

As of this date, 7 June 2023, the Company has been informed that the following primary insiders and close associates in the Company have exercised their subscription rights, as set out below:

Anders Tullgren, Chairman of the Board of Directors of the Company, has on 5 June 2023, exercised 1,409,872 subscription rights in the Rights Issue, entitling Anders Tullgren to be allocated 1,409,872 offer shares in the Rights Issue at a price per offer share of NOK 0.10, subject to the Rights Issue being completed.

Svev AS, a company closely associated to Sveinung Hole which is a member of the Board of Directors of the Company, has on 6 June 2023 exercised 2,000,000 subscription rights in the Rights Issue, entitling Svev AS to be allocated 2,000,000 offer shares in the Rights Issue at a price per offer share of NOK 0.10, subject to the Rights Issue being completed.

As of this date, 7 June 2023, the Company has been informed that the following primary insiders and close associates in the Company have sold subscription rights, as set out below:

Sveinung Hole, member of the Board of Directors of the Company, has on 6 June 2023 sold 83,182 subscription rights of his total holding of 83,182 subscription rights in the Rights Issue.

Svev AS, a company closely associated to Sveinung Hole which is a member of the Board of Directors of the Company, has on 6 June 2023 sold 945,053 subscription rights of its total holding of 2,945,053 subscription rights in the Rights Issue.

Sarsia Seed AS, a company closely associated to Sveinung Hole which is a member of the Board of Directors of the Company, has on 6 June 2023 sold 44,000,000 subscription rights of its total holding of 59,719,358 subscription rights in the Rights Issue.  

The following primary insiders and close associates in the Company have sold and purchased shares in the Company, as set out below: 

Sveinung Hole, member of the Board of Directors of the Company, has on 6 June 2023 sold 2,950 shares in the Company of his total holding of 2,950 shares in the Company.

Svev AS, a company closely associated to Sveinung Hole who is a member of the Board of Directors of the Company, has on 6 June 2023 purchased 2,950 shares in the Company. In addition, Svev AS has on 6 June 2023 sold 107,394 shares in the Company of its total holding of 107,394 shares in the Company.

Please see further details about the transactions in the attached forms.

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

Attachments
PDF

PDF

PDF

About Oncoinvent

Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.

Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close